Search Results
Search for other papers by Francesco Boi in
Google Scholar
PubMed
Search for other papers by Fabiana Pani in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
The association between Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) has been originally suggested by retrospective pathological studies and has recently been re-evaluated and proposed on the basis of several fine-needle aspiration cytology (FNAC) studies. In FNAC studies, the association between HT and PTC is based on the comparison of anti-thyroid autoantibodies (ATA) (anti-thyroperoxidase [TPOAb] and anti-thyroglobulin [TgAb]), thyroid function (TSH), and cytology with histology of thyroid nodules and lymphocytic thyroid infiltration (LTI) of operated thyroid glands. Most of the pathological studies found a high prevalence rate of PTC in HT. In most FNAC studies, the risk ratio of PTC in HT patients was evaluated using multivariate statistical analysis: increased TSH levels represented the main and common independent risk factor of malignancy, although it resulted not consistently related to HT. On the other hand, several studies provided a positive relationship between ATA and PTC, particularly with TgAb. Two recent FNAC studies from the same referral center clearly demonstrated an independent risk for thyroid malignancy conferred by both TPOAb and TgAb, confirming the role of increased TSH levels, and found a significant association between PTC and ATA and diffuse LTI at histology. These studies are consistent with the hypothesis that autoimmune thyroid inflammation and increased serum TSH concentration may be involved in thyroid tumor growth. The complex relationship between HT and PTC, which involves immunological/hormonal pathogenic links, needs to be further investigated with prospective studies.
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Luca Chiovato in
Google Scholar
PubMed
Search for other papers by Gianfranco Fenzi in
Google Scholar
PubMed
Search for other papers by Claudio Marocci in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
Search for other papers by Enio Martino in
Google Scholar
PubMed
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Giovanna Rotondo Dottore in
Google Scholar
PubMed
Search for other papers by Marenza Leo in
Google Scholar
PubMed
Department of Surgical, Medical and Molecular Pathology, Division of Thoracic Surgery, University of Pisa and University Hospital of Pisa, Pisa, Italy
Search for other papers by Roberta Ricciardi in
Google Scholar
PubMed
Search for other papers by Michelangelo Maestri in
Google Scholar
PubMed
Search for other papers by Ilaria Bucci in
Google Scholar
PubMed
Search for other papers by Marco Lucchi in
Google Scholar
PubMed
Search for other papers by Franca Melfi in
Google Scholar
PubMed
Search for other papers by Melania Guida in
Google Scholar
PubMed
Search for other papers by Anna De Rosa in
Google Scholar
PubMed
Search for other papers by Loredana Petrucci in
Google Scholar
PubMed
Search for other papers by Ilaria Ionni in
Google Scholar
PubMed
Search for other papers by Giulia Lanzolla in
Google Scholar
PubMed
Search for other papers by Francesca Nicolì in
Google Scholar
PubMed
Search for other papers by Michele Mantuano in
Google Scholar
PubMed
Search for other papers by Debora Ricci in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Michele Marinò in
Google Scholar
PubMed
Objectives: The thymus plays a central role in immune tolerance, which prevents autoimmunity. Myasthenia gravis (MG) is commonly associated with thymoma or thymus hyperplasia, and it can coexist with autoimmune thyroid diseases. However, the role of the thymus in thyroid autoimmunity remains to be clarified, which we investigated here. Study Design: The study design entailed the inclusion of consecutive MG patients and the measurement of anti-thyroid autoantibodies at baseline and, limited to autoantibody-positive patients, also at 24 and 48 weeks. One hundred and seven MG patients were studied. The main outcome measure was the behaviour of anti-thyroglobulin autoantibodies (TgAbs) and anti-thyroperoxidase autoantibodies (TPOAbs) over time in relation to thymectomy. Results: Serum TgAbs and/or TPOAbs were detected in ∼20% of patients in the absence of thyroid dysfunction. The prevalence of positive serum TgAbs and/or TPOAbs decreased significantly (p = 0.002) over the follow-up period in patients who underwent thymectomy, but not in patients who were not thymectomized. When the analysis was restricted to TgAbs or TPOAbs, findings were similar. On the same line, there was a general trend towards a reduction in the serum concentrations of anti-thyroid autoantibodies in patients who underwent thymectomy, which was significant for TPOAbs (p = 0.009). Conclusions: Our findings suggest a role of the thymus in the maintenance of humoral thyroid autoimmunity.
